1
|
Olivares Hernandez A, García J, Alonso N, Corchete Sánchez L, Perez García J, Mesia Nin R, Rubió-Casadevall J, Garcia Giron C, Iglesias Docampo L, Carral Maseda A, Taberna Sanz M, Vazquez S, Gómez Muñoz A, del Barco E, González Sarmiento R, Cruz Hernandez J. 701P Genomic alteration relationships with toxicity to TPF induction chemotherapy in head and neck squamous cell carcinoma patients participating in a clinical trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Goodman-Meza D, Tang A, Aryanfar B, Vazquez S, Gordon AJ, Goto M, Goetz MB, Shoptaw S, Bui AAT. Natural Language Processing and Machine Learning to Identify People Who Inject Drugs in Electronic Health Records. Open Forum Infect Dis 2022; 9:ofac471. [PMID: 36168546 PMCID: PMC9511274 DOI: 10.1093/ofid/ofac471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Accepted: 09/08/2022] [Indexed: 11/15/2022] Open
Abstract
Background Improving the identification of people who inject drugs (PWID) in electronic medical records can improve clinical decision making, risk assessment and mitigation, and health service research. Identification of PWID currently consists of heterogeneous, nonspecific International Classification of Diseases (ICD) codes as proxies. Natural language processing (NLP) and machine learning (ML) methods may have better diagnostic metrics than nonspecific ICD codes for identifying PWID. Methods We manually reviewed 1000 records of patients diagnosed with Staphylococcus aureus bacteremia admitted to Veterans Health Administration hospitals from 2003 through 2014. The manual review was the reference standard. We developed and trained NLP/ML algorithms with and without regular expression filters for negation (NegEx) and compared these with 11 proxy combinations of ICD codes to identify PWID. Data were split 70% for training and 30% for testing. We calculated diagnostic metrics and estimated 95% confidence intervals (CIs) by bootstrapping the hold-out test set. Best models were determined by best F-score, a summary of sensitivity and positive predictive value. Results Random forest with and without NegEx were the best-performing NLP/ML algorithms in the training set. Random forest with NegEx outperformed all ICD-based algorithms. F-score for the best NLP/ML algorithm was 0.905 (95% CI, .786-.967) and 0.592 (95% CI, .550-.632) for the best ICD-based algorithm. The NLP/ML algorithm had a sensitivity of 92.6% and specificity of 95.4%. Conclusions NLP/ML outperformed ICD-based coding algorithms at identifying PWID in electronic health records. NLP/ML models should be considered in identifying cohorts of PWID to improve clinical decision making, health services research, and administrative surveillance.
Collapse
Affiliation(s)
- David Goodman-Meza
- Correspondence: David Goodman-Meza, MD, MAS, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, CHS 52-215, Los Angeles, CA, 90095-1688 ()
| | - Amber Tang
- Department of Internal Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
| | - Babak Aryanfar
- Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA
| | - Sergio Vazquez
- Undergraduate Studies, Dartmouth College, Hanover, New Hampshire, USA
| | - Adam J Gordon
- Informatics, Decision-Enhancement, and Analytic Sciences Center, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah, USA
- Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA
| | - Michihiko Goto
- Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA
- Center for Access and Delivery Research and Evaluation, Iowa City Veterans Affairs Medical Center, Iowa City, Iowa, USA
| | - Matthew Bidwell Goetz
- Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA
- Department of Internal Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
| | - Steven Shoptaw
- Department of Family Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
| | | |
Collapse
|
3
|
García J, Olivares Hernandez A, Alonso N, Corchete Sánchez L, Fernandez-Mateos J, Perez García J, Hernández M, Seijas Tamayo R, Mesia Nin R, Rubió-Casadevall J, Garcia Giron C, Iglesias L, Carral Maseda A, Adansa Klain J, Taberna Sanz M, Vazquez S, Gómez Muñoz A, del Barco E, González Sarmiento R, Cruz Hernandez J. 692P Copy number alterations and response to radiotherapy + cisplatin vs radiotherapy + cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
4
|
Beman JM, Vargas SM, Wilson JM, Perez-Coronel E, Karolewski JS, Vazquez S, Yu A, Cairo AE, White ME, Koester I, Aluwihare LI, Wankel SD. Substantial oxygen consumption by aerobic nitrite oxidation in oceanic oxygen minimum zones. Nat Commun 2021; 12:7043. [PMID: 34857761 PMCID: PMC8639706 DOI: 10.1038/s41467-021-27381-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Accepted: 11/15/2021] [Indexed: 01/04/2023] Open
Abstract
Oceanic oxygen minimum zones (OMZs) are globally significant sites of biogeochemical cycling where microorganisms deplete dissolved oxygen (DO) to concentrations <20 µM. Amid intense competition for DO in these metabolically challenging environments, aerobic nitrite oxidation may consume significant amounts of DO and help maintain low DO concentrations, but this remains unquantified. Using parallel measurements of oxygen consumption rates and 15N-nitrite oxidation rates applied to both water column profiles and oxygen manipulation experiments, we show that the contribution of nitrite oxidation to overall DO consumption systematically increases as DO declines below 2 µM. Nitrite oxidation can account for all DO consumption only under DO concentrations <393 nM found in and below the secondary chlorophyll maximum. These patterns are consistent across sampling stations and experiments, reflecting coupling between nitrate reduction and nitrite-oxidizing Nitrospina with high oxygen affinity (based on isotopic and omic data). Collectively our results demonstrate that nitrite oxidation plays a pivotal role in the maintenance and biogeochemical dynamics of OMZs.
Collapse
Affiliation(s)
- J. M. Beman
- grid.266096.d0000 0001 0049 1282Life and Environmental Sciences, University of California, Merced, Merced, CA USA
| | - S. M. Vargas
- grid.266096.d0000 0001 0049 1282Life and Environmental Sciences, University of California, Merced, Merced, CA USA
| | - J. M. Wilson
- grid.266096.d0000 0001 0049 1282Life and Environmental Sciences, University of California, Merced, Merced, CA USA ,grid.266100.30000 0001 2107 4242Scripps Institution of Oceanography, University of California, San Diego, CA USA
| | - E. Perez-Coronel
- grid.266096.d0000 0001 0049 1282Life and Environmental Sciences, University of California, Merced, Merced, CA USA
| | - J. S. Karolewski
- grid.56466.370000 0004 0504 7510Marine Chemistry and Geochemistry, Woods Hole Oceanographic Institution, Woods Hole, MA USA
| | - S. Vazquez
- grid.266096.d0000 0001 0049 1282Life and Environmental Sciences, University of California, Merced, Merced, CA USA
| | - A. Yu
- grid.266096.d0000 0001 0049 1282Life and Environmental Sciences, University of California, Merced, Merced, CA USA
| | - A. E. Cairo
- grid.266096.d0000 0001 0049 1282Life and Environmental Sciences, University of California, Merced, Merced, CA USA
| | - M. E. White
- grid.266100.30000 0001 2107 4242Scripps Institution of Oceanography, University of California, San Diego, CA USA
| | - I. Koester
- grid.266100.30000 0001 2107 4242Scripps Institution of Oceanography, University of California, San Diego, CA USA
| | - L. I. Aluwihare
- grid.266100.30000 0001 2107 4242Scripps Institution of Oceanography, University of California, San Diego, CA USA
| | - S. D. Wankel
- grid.56466.370000 0004 0504 7510Marine Chemistry and Geochemistry, Woods Hole Oceanographic Institution, Woods Hole, MA USA
| |
Collapse
|
5
|
Perez Navarro E, Conteduca V, Gonzalez del Alba A, Mellado B, Cremaschi P, Fernandez Calvo O, Mendez Vidal M, Climent Duran M, Duran I, Gallardo Diaz E, Vazquez S, Font Pous A, Gurioli G, Martínez A, López Andreo M, Attard G, Castellano Gauna D, Grande E, Giorgi U, Gonzalez Billalabeitia E. 589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
6
|
Duran MC, Vidal N, Pérez S, Méndez-Vidal M, Anguera G, Salas IM, Gallardo E, Cuellar M, Soto J, Martín A, Domènech M, Rodriguez-Vida A, Casado EA, Diaz-Mejía N, Kareaga MM, Calvo OF, Guzmán JV, Vazquez S, Gonzalez del Alba A, Puente J. 1572P The impact of COVID-19 pandemic on Spanish genitourinary (GU) cancer patients: SOGUG-COVID-19 study. Ann Oncol 2021. [PMCID: PMC8454367 DOI: 10.1016/j.annonc.2021.08.1565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
7
|
González Del Alba A, Méndez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clin Transl Oncol 2021; 23:969-979. [PMID: 33625671 PMCID: PMC8057980 DOI: 10.1007/s12094-021-02561-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/27/2021] [Indexed: 12/24/2022]
Abstract
The treatment of advanced prostate cancer has evolved due to recent advances in molecular research and new drug development. Dynamic aberrations in the androgen receptor, DNA repair genes, PTEN-PI3K, and other pathways drive the behavior of advanced prostate cancer allowing a better selection of therapies in each patient. Tumor testing for BRCA1 and BRCA2 is recommended for patients with metastatic prostate cancer, also considering a broad panel to guide decisions and genetic counseling. In symptomatic metastatic patients, castration should be stared to palliate symptoms and prolong survival. In high-risk or high-volume metastatic hormone-naïve patients, castration should be combined with docetaxel, abiraterone, enzalutamide or apalutamide. Radiotherapy to the primary tumor combined with systemic therapy is recommended in low-volume mHNPC patients. In patients with non-metastatic castration-resistant tumors, risk stratification can define the frequency of imaging. Adding enzalutamide, darolutamide or apalutamide to these patients prolongs metastasis-free and overall survival, but potential adverse events need to be taken into consideration. The choice of docetaxel, abiraterone or enzalutamide for treating metastatic castration-resistant patients depends on previous therapies, with cabazitaxel being also recommended after docetaxel. Olaparib is recommended in BRCA1/BRCA2 mutated castration-resistant patients after progression on at least one new hormonal therapy. Aggressive variants of prostate cancer respond to platinum-based chemotherapy. To optimize treatment efficiency, oncologists should incorporate all of these advances into an overall therapeutic strategy.
Collapse
Affiliation(s)
- A González Del Alba
- Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Joaquin Rodrigo 2, Majadahonda, 28222, Madrid, Spain.
| | - M J Méndez-Vidal
- Medical Oncology Department, Hospital Universitario Reina Sofía, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Córdoba, Spain
| | - S Vazquez
- Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
| | - E Castro
- Medical Oncology Department, Hospital Universitario Virgen de la Victoria y Regional de Mälaga, Málaga, Spain
| | - M A Climent
- Medical Oncology Department, Fundación Instituto Valenciano de Oncología, València, Spain
| | - E Gallardo
- Medical Oncology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain
| | - E Gonzalez-Billalabeitia
- Medical Oncology Department, Hospital Universitario Doce de Octubre, Instituto Imas12, Madrid, Spain
- Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain
| | - D Lorente
- Medical Oncology Department, Hospital Provincial de Castellón, Castellon, Spain
| | - J P Maroto
- Medical Oncology Department, Hospital Universitari Santa Creu i San Pau, Barcelona, Spain
| | - J A Arranz
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| |
Collapse
|
8
|
Vethencourt A, Trinidad E, Gómez Aleza C, Pernas Simon S, Petit A, Soler T, Urruticoechea A, Gumà Martinez A, García-Tejedor A, Pla M, Capó C, Gil MG, Stradella A, Fernádez A, Recalde Penabad S, Cejuela M, Vazquez S, Iserte A, Falo C, Gonzalez-Suarez E. 14P Immunomodulatory effect of denosumab in early breast cancer: Preliminary results of a randomized window-opportunity clinical trial D-Biomark. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
9
|
de la Rosa R, Vazquez S, Tachachartvanich P, Daniels SI, Sillé F, Smith MT. Cell-Based Bioassay to Screen Environmental Chemicals and Human Serum for Total Glucocorticogenic Activity. Environ Toxicol Chem 2021; 40:177-186. [PMID: 33085113 PMCID: PMC7793542 DOI: 10.1002/etc.4903] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Revised: 06/24/2020] [Accepted: 10/12/2020] [Indexed: 05/27/2023]
Abstract
Glucocorticoids are steroid hormones that have systemic effects that are mediated by the glucocorticoid receptor. Environmental chemicals that disrupt glucocorticoid receptor signaling and/or glucocorticoid homeostasis could adversely affect the health of human and nonhuman vertebrates. A major challenge in identifying environmental chemicals that alter glucocorticoid receptor signaling and/or glucocorticoid homeostasis is a lack of adequate screening methods. We developed a cell-based bioassay to measure total glucocorticogenic activity (TGA) of environmental chemicals and human serum. Human MDA-MB-231 breast cancer cells were stably transfected with a luciferase reporter gene driven by 3 tandem glucocorticoid-response elements. Dose-response curves for 6 glucocorticoids and 4 non-glucocorticoid steroid hormones were generated to evaluate the specificity of the bioassay. Cells were also optimized to measure TGA of 176 structurally diverse environmental chemicals and human serum samples in a high-throughput format. Reporter activity was glucocorticoid-specific and induced 400-fold by 1 μM dexamethasone. Furthermore, 3 of the screened chemicals (3,4,4'-trichlorocarbanilide, isopropyl-N-phenylcarbamate, and benzothiazole derivative 2-[4-chlorophenyl]-benzothiazole) potentiated cortisol-induced glucocorticoid receptor activity. Serum TGA estimates from the bioassay were highly correlated with a cortisol enzyme-linked immunosorbent assay. The present study establishes an in vitro method to rapidly screen environmental chemicals and human serum for altered glucocorticogenic activity. Future studies can utilize this tool to quantify the joint effect of endogenous glucocorticoids and environmental chemicals. Environ Toxicol Chem 2021;40:177-186. © 2020 SETAC.
Collapse
Affiliation(s)
- Rosemarie de la Rosa
- Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA
| | - Sergio Vazquez
- Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA
| | - Phum Tachachartvanich
- Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA
| | - Sarah I. Daniels
- Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA
| | - Fenna Sillé
- Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - Martyn T. Smith
- Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA
| |
Collapse
|
10
|
Martin De Miguel I, Fernandez A, Lozano N, Gutierrez-Ibanes E, Sanz Ruiz R, Diez-Delhoyo F, Vazquez S, Reigadas E, Garcia De Viedma D, Elizaga Corrales J, Fernandez-Aviles F, Bermejo J. Gut microbiota profile of patients with acute coronary syndrome, effect of the most frequent comorbidities. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Gut microbiota dysbiosis may modify the inflammatory state, which could trigger the development of acute coronary syndrome (ACS). Moreover, cardiovascular risk factors may alter the microbiota profile involved in ACS development.
Purpose
To address the potential role of alterations in microbiota as triggers of ACS and their cardiovascular comorbidities in patients with ACS.
Methods
Patients admitted for ACS were prospectively included. Stool samples were collected in the first 24 hours after admission. For microbiota analysis, Operational Taxonomic Unit (OTUs) method from V4 amplicon of 16S rRNA was employed. Identification, quantification, clusterization and taxonomic classification of OTUs was performed in Mothur through RDP database. ACS patient microbiota was compared with the microbiota of 10 healthy controls. The microbiota changes analyses were evaluated with ANOVA analysis.
Results
41 ACS patients with a mean age of 62±11 years old were included. 34 (83%) were males, 17 (42%) suffered arterial hypertension, 18 (44%) dyslipidaemia, 37 (90%) diabetes mellitus and 16 (39%) were current smokers. A multidimensional scaling model allowed us to clearly delineate different clusters between patients with ACS and healthy controls. This was due to important differences in the main phylum of the human microbiota (Table) Bacteroidetes, Firmicutes / Bacteroidetes ratio and Actinobacteria. In addition, there was a significant decrease in protective Cyanobacteria (p=0.03) and Proteobacteria (p=0.04) in men. Hypertensive and dyslipidaemic patients had a significantly higher amount of Firmicutes, Clostridia (p=0.05) and Erysipelotrichia (p=0.03) classes, respectively. Patients with diabetes had significantly less protective Proteobacteria (p=0.002) and Spirochaetes (p=0.04). Finally, smoking was associated with a significant increase in pathogenic Lentisphaerae (p=0.04).
Conclusions
Patients with ACS have clear pathogenic alterations of their gut microbiota. Classical cardiovascular risk factors induce different patterns of gut dysbiosis.
Gut microbiota profile.
Funding Acknowledgement
Type of funding source: Public Institution(s). Main funding source(s): Carlos III Health Institute
Collapse
Affiliation(s)
| | - A.I Fernandez
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - N Lozano
- University Hospital Gregorio Maranon, Madrid, Spain
| | | | - R Sanz Ruiz
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - F Diez-Delhoyo
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| | - S Vazquez
- University Hospital Gregorio Maranon, Madrid, Spain
| | - E Reigadas
- University Hospital Gregorio Maranon, Madrid, Spain
| | | | | | | | - J Bermejo
- University Hospital Gregorio Maranon, Cardiology, Madrid, Spain
| |
Collapse
|
11
|
Ciruelos E, Villagrasa P, Oliveira M, Pernas Simon S, Cortés J, Vazquez S, Martínez N, Perelló A, Bermejo De Las Heras B, Martínez E, Garau Llinas I, Mele Olive M, Montaño A, Vega E, Cantos B, Echarri M, Pascual T, Celiz P, González-Farré X, Prat A. 180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.03.280] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
12
|
Campelo RG, Rivera FV, Firvida X, Lazaro M, Vazquez S, Isla D, Majem M, De Castro Carpeno J, Viñolas N. EP1.16-01 A Spanish Initiative to Know the Unmet Needs of Women with Lung Cancer: "Circulos Program". J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Angelats L, Campelo RG, Bernabe R, Arriola E, Rocha P, De Juan VC, Sais E, Barba A, Viñolas N, Moreno MG, Vilà L, Juan O, Vilariño N, Cobo M, Domine M, Vazquez S, Coves J, Marse-Fabregat R, Gomez AE, Carcereny E. P1.01-93 Metastases Sites as a Prognostic Factor in a Real-World Multicenter Cohort Study of Spanish ALK-Positive NSCLC Patients (p). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Cepas Guillen PL, Borrego-Rodriguez J, Flores-Umanzor E, Fernandez-Valledor A, Vazquez S, Echarte Morales JC, Menendez-Suarez P, Iglesias Garriz I, Perez De Prado A, Regueiro A, Brugaletta S, Freixa X, Masotti M, Fernandez-Vazquez F, Sabate M. P1562Outcomes of nonagenarians with ST elevation myocardial infarction. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Developed countries are facing a sustained increase in life expectancy. Elderly people represent the fastest growing portion of cardiovascular patients. However, nonagenarians with ST-segment elevation myocardial infarction (STEMI) are often underrepresented in clinical trials as prolonged follow-up may be compromised by limited life expectancy. The aim of this retrospective study is to analyse the clinical presentation, risk factors, co-morbidities, outcomes of nonagenarian patients presenting with STEMI.
Methods
We included all consecutive nonagenarians presenting with STEMI admitted in 2 academic centers between 2007 and 2017. There were no exclusion criteria. We collected demographic, clinical, and procedural data. All-cause mortality was assessed in-hospital, at 6 months and at 1-year follow-up.
Results
A total of 140 patients (mean age 91.6 years [91.3–92]; 59% females) were included. The number of patients increased over the years (from 6.5 cases per year before 2012 to 14.4 cases per year after 2012). One out of 5 patients presented disability or dependence for activities of daily living (ADL). Emergent catheterization was performed in 70% of our patients, and primary percutaneous coronary intervention (pPCI) in 57% (n=80). The use of bare metal stent was preponderant (72%) in this cohort. Successful revascularization of the culprit vessel was achieved in 90% of patients. Dual antiplatelet therapy with aspirin and clopidogrel was used in 97% of patients. Overall, in-hospital mortality was 22%, increased up to 27% at 6 months and up to 34% at 1-year follow-up. In-hospital mortality was lower in pPCI group than in conservative group (13.7% versus 31.6%, adjusted OR: 0.17, 95% CI: 0.04–0.67, P<0.01). One-year mortality was also lower in pPCI group than in conservative group (26% versus 45%, P<0.01). Multivariable analysis identified mechanical complications (adjusted OR: 28.1, 95% CI: 3.18–247.7, P<0.01), Killip class (III/IV) (adjusted OR: 4.19, 95% CI: 3.37–22.3, P<0.01) and pPCI (adjusted OR: 0.40, 95% CI: 0. 16- 0. 95, P<0.05) as independent predictors of all-cause mortality at 1 year.
Conclusions
STEMI in nonagenarians is becoming more and more common. pPCI may be also the preferred strategy in this high-risk cohort. The hemodynamic compromise (Killip class III/IV), the presence of complications related to myocardial infarction and early revascularization may be related to prognosis of these patients.
Collapse
Affiliation(s)
| | | | | | | | - S Vazquez
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | | | | | | | | | - A Regueiro
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - S Brugaletta
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - X Freixa
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - M Masotti
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | | | - M Sabate
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| |
Collapse
|
15
|
Fernandez S, Garcia A, Vethencourt A, Vazquez S, Petit A, Pla MJ, Ortega R, Pérez J, Gil M, Ponce J, Pernas S, Lopez A, Falo C. Abstract P2-08-58: Prognostic factors of survival in node positive breast cancer patients after neoadjuvant chemotherapy in a large series after 5y follow-up: Can response overcome the poor prognosis of nodal stage? Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Status of the axilla is one of the most significant prognostic factors in breast cancer (BC) patients. On the other hand, response to neoadjuvant chemotherapy (NACT) is related to survival. The aim of the present study is to analyze which prognostic factors impact most on Node positive (N+) BC patient survival after NATC. Material and methods: Retrospective analyses on a series of N+ BC patients treated with NATC based on anthracyclines and taxanes +/- trastuzumab if HER2 positive tumors, between June 2008 and December 2016. Clinical, radiological and pathological outcomes have been evaluated. Residual cancer burden (RCB) 1 and the neoadjuvant response index (INR) 2 have been recorded. Survival was calculated with Kaplan-Meier survival curve since the start of NATC to the first documented disease recurrence (DFS) or death (OS). Hazard ratios (HRs) with 95% CIs were estimated with cox proportional hazards regression analysis and subgroups were compared with a two-sided log-rank test. Results: A total of 345 N+ BC patients were included. Pathological complete response was achieved in 72 (20.8%) patients. After NACT, 137 (39.6%) become ypN0, 9 (2.6%) ypN1 mic, 113 (32.7%) ypN1, 60 (17.3%) ypN2 and 26 (7.6%) N3. Those independent predictive factor of ypN0 were molecular subtype (TN and Her2+) with OR: 7.7, p<0.001 and clinical response with OR 6.88, p: 0.04. At a mean follow-up of 58 months there have been 73 (21.1%) recurrences: 9 (2.3%) local, 45 (13%) systemic, 15 (4.3%) systemic+ local, 3 (0.9%) axilla, 1 (0.3%) supraclavicular. The estimated 5y OS was 87.8%. The univariate analysis according to DSF is detailed in Table1.
Adjusted univariate anaalysis cox regression of clinical and pathological factors of desease free survivalBMI10.989-1.010.963AGE0.9960.953-1.0420.876Dose NATC0.9940.979-1.0080.402Clinical Stage1.4021.077-1.8260.012Rx Image1.260.803-1.9940.311Rx size1.0090.995-1.0240.217Number suspicious ALN1.0950.801-1.4970.57Molecular subtype TN,HER20.8800.534-1.450.616Nottinghan grade1.0460.753-1.4530.789Histological subtype1.4651.044-2.0570.27MOlecular subtype1.1510.956-1.3850.137Vascular invasion1.6761.137-24710.009Clinical response2.3691.709-3.284<0.001Fibrosis tumor bed0.980.972-0.989<0.001Nodal fibrosis>50%1.7950.874-3.6860.111Pathological tumoral response1.6861.175-2.4180.005ypN03.561.853-6.838<0.001NRI0.330.192-0.565<0.001RCB1.2741.106-1.4680.001
In the multivariate model those parameters that were independently prognostic were clinical response HR: 5.44 (IC95% 2.275-13.042, p<0.001) and clinical stage HR: 2.364 (IC95% 1.018-5.490, p: 0.045). Conclusions: The most significant prognostic factor in our N+ series was response to NATC, followed by clinical stage. Those independently predictive factors of axillar response (ypN0) were molecular subtype (TN and Her2+) and clinical response. In conclusion, in those patients with chemo sensitive tumors, lymphadenectomy could be safely spared with a more selective axillary approach.
Citation Format: Fernandez S, Garcia A, Vethencourt A, Vazquez S, Petit A, Pla MJ, Ortega R, Pérez J, Gil M, Ponce J, Pernas S, Lopez A, Falo C. Prognostic factors of survival in node positive breast cancer patients after neoadjuvant chemotherapy in a large series after 5y follow-up: Can response overcome the poor prognosis of nodal stage? [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-58.
Collapse
Affiliation(s)
- S Fernandez
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - A Garcia
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - A Vethencourt
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - S Vazquez
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - A Petit
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - MJ Pla
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - R Ortega
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - J Pérez
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - M Gil
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - J Ponce
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - S Pernas
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - A Lopez
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - C Falo
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| |
Collapse
|
16
|
Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 2019; 37:490-503. [PMID: 30625039 DOI: 10.1200/jco.18.00358] [Citation(s) in RCA: 224] [Impact Index Per Article: 44.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
PURPOSE Germline mutations in DNA damage repair (DDR) genes are identified in a significant proportion of patients with metastatic prostate cancer, but the clinical implications of these genes remain unclear. This prospective multicenter cohort study evaluated the prevalence and effect of germline DDR (gDDR) mutations on metastatic castration-resistance prostate cancer (mCRPC) outcomes. PATIENTS AND METHODS Unselected patients were enrolled at diagnosis of mCRPC and were screened for gDDR mutations in 107 genes. The primary aim was to assess the impact of ATM/BRCA1/BRCA2/ PALB2 germline mutations on cause-specific survival (CSS) from diagnosis of mCRPC. Secondary aims included the association of gDDR subgroups with response outcomes for mCRPC treatments. Combined progression-free survival from the first systemic therapy (PFS) until progression on the second systemic therapy (PFS2) was also explored. RESULTS We identified 68 carriers (16.2%) of 419 eligible patients, including 14 with BRCA2, eight with ATM, four with BRCA1, and none with PALB2 mutations. The study did not reach its primary end point, because the difference in CSS between ATM/BRCA1/BRCA2/PALB2 carriers and noncarriers was not statistically significant (23.3 v 33.2 months; P = .264). CSS was halved in germline BRCA2 (g BRCA2) carriers (17.4 v 33.2 months; P = .027), and g BRCA2 mutations were identified as an independent prognostic factor for CCS (hazard ratio [HR], 2.11; P = .033). Significant interactions between g BRCA2 status and treatment type (androgen signaling inhibitor v taxane therapy) were observed (CSS adjusted P = .014; PFS2 adjusted P = .005). CSS (24.0 v 17.0 months) and PFS2 (18.9 v 8.6 months) were greater in g BRCA2 carriers treated in first line with abiraterone or enzalutamide compared with taxanes. Clinical outcomes did not differ by treatment type in noncarriers. CONCLUSION g BRCA2 mutations have a deleterious impact on mCRPC outcomes that may be affected by the first line of treatment used. Determination of g BRCA2 status may be of assistance for the selection of the initial treatment in mCRPC. Nonetheless, confirmatory studies are required before these results can support a change in clinical practice.
Collapse
Affiliation(s)
- Elena Castro
- 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain.,2 Hospital Universitario Quiron, Madrid, Spain
| | - Nuria Romero-Laorden
- 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain.,3 Hospital Universitario La Princesa, Madrid, Spain
| | - Angela Del Pozo
- 4 Institute of Medical and Molecular Genetics, Hospital Universitario La Paz, and CIBERER Instituto de Salud Carlos III, Madrid, Spain
| | - Rebeca Lozano
- 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain.,5 CNIO_IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga, Málaga Spain
| | - Ana Medina
- 6 Centro Oncológico de Galicia, Coruña, Spain
| | - Javier Puente
- 7 Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
| | - Josep Maria Piulats
- 8 Institut Català d'Oncologia, Bellvitge Biomedical Research Institute, Barcelona, Spain
| | | | - Maria Isabel Saez
- 5 CNIO_IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga, Málaga Spain.,10 Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, Spain
| | - Rafael Morales-Barrera
- 11 Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | | | - Ylenia Cendón
- 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain.,13 Universidad Autónoma de Madrid, Madrid, Spain
| | | | | | | | - Alvaro Montesa
- 5 CNIO_IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga, Málaga Spain.,10 Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, Spain
| | - Paz Nombela
- 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain
| | | | | | | | - Kristina Ibáñez
- 4 Institute of Medical and Molecular Genetics, Hospital Universitario La Paz, and CIBERER Instituto de Salud Carlos III, Madrid, Spain
| | | | - Lorena Magraner-Pardo
- 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain
| | | | - Elena Vallespín
- 4 Institute of Medical and Molecular Genetics, Hospital Universitario La Paz, and CIBERER Instituto de Salud Carlos III, Madrid, Spain
| | - Enrique Gallardo
- 22 Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain
| | | | | | - Pablo Lapunzina
- 4 Institute of Medical and Molecular Genetics, Hospital Universitario La Paz, and CIBERER Instituto de Salud Carlos III, Madrid, Spain
| | - David Olmos
- 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain.,5 CNIO_IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga, Málaga Spain
| |
Collapse
|
17
|
González Del Alba A, De Velasco G, Lainez N, Maroto P, Morales-Barrera R, Muñoz-Langa J, Pérez-Valderrama B, Basterretxea L, Caballero C, Vazquez S. SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). Clin Transl Oncol 2018; 21:64-74. [PMID: 30565086 PMCID: PMC6339669 DOI: 10.1007/s12094-018-02001-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2018] [Accepted: 11/26/2018] [Indexed: 12/24/2022]
Abstract
The goal of this article is to provide recommendations about the management of muscle-invasive (MIBC) and metastatic bladder cancer. New molecular subtypes of MIBC are associated with specific clinical–pathological characteristics. Radical cystectomy and lymph node dissection are the gold standard for treatment and neoadjuvant chemotherapy with a cisplatin-based combination should be recommended in fit patients. The role of adjuvant chemotherapy in MIBC remains controversial; its use must be considered in patients with high-risk who are able to tolerate a cisplatin-based regimen, and have not received neoadjuvant chemotherapy. Bladder-preserving approaches are reasonable alternatives to cystectomy in selected patients for whom cystectomy is not contemplated either for clinical or personal reasons. Cisplatin-based combination chemotherapy is the standard first-line protocol for metastatic disease. In the case of unfit patients, carboplatin–gemcitabine should be considered the preferred first-line chemotherapy treatment option, while pembrolizumab and atezolizumab can be contemplated for individuals with high PD-L1 expression. In cases of progression after platinum-based therapy, PD-1/PD-L1 inhibitors are standard alternatives. Vinflunine is another option when anti-PD-1/PD-L1 therapy is not possible. There are no data from randomized clinical trials regarding moving on to immuno-oncology agents.
Collapse
Affiliation(s)
- A González Del Alba
- Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Joaquin Rodrigo 2, 28222, Majadahonda, Madrid, Spain.
| | - G De Velasco
- Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain
| | - N Lainez
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - P Maroto
- Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - R Morales-Barrera
- Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Barcelona, Spain
| | - J Muñoz-Langa
- Medical Oncology Department, Hospital Universitari I Politècnic la Fe, Valencia, Spain
| | - B Pérez-Valderrama
- Medical Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain
| | - L Basterretxea
- Medical Oncology Department, Hospital Donostia-Donostia Ospitalea, Donostia, Spain
| | - C Caballero
- Medical Oncology Department, Ciberonc, Centro de Investigación Biomédica en Red Cáncer. Hospital General Universitario de Valencia, Valencia, Spain
| | - S Vazquez
- Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
| |
Collapse
|
18
|
Marín J, Oliva Bernal M, Plana Serrahima M, Ferrer M, Vilariño Quintela N, Vazquez S, Vilajosana E, Lozano A, Nogués J, Marí A, Bermejo O, Mesia Nin R, Taberna Sanz M. Paclitaxel in combination with anti-EGFR therapy as induction chemotherapy for patients unfit for cisplatin with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Soler G, Ruffinelli Rodriguez J, Legido R, Martinez Villacampa M, Perez F, Pardo-Burdalo B, Marín J, Morilla Ruiz I, Heras Lopez L, Vazquez S, Recalde S, Plana Serrahima M, Santos C, Mulet Margalef N, Teule A, Salazar R, Galan M, Saldaña J. Detection of frailty in elderly colorectal càncer patients: Is G8 a good screening tool? Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Procopio G, Bamias A, Schmidinger M, Hawkins R, Rodriguez Sanchez A, Vazquez S, Srihari N, Kalofonos H, Bono P, Pisal C, Hirschberg Y, Dezzani L, Ahmad Q, Suarez Rodriguez C, Jonasch E. Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy283.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Cepas Guillen PL, Flores Umanzor E, Martin Yuste V, Fernandez Valledor A, Vazquez S, Pujol Lopez M, San Antonio R, Caldentey G, Ivey Miranda J, Jimenez Britez G, Regueiro A, Freixa X, Ferreira I, Sabate M. P3476Long-term survival benefit of CTO revascularisation vs. conservative treatment in elderly patients. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | | | - V Martin Yuste
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | | | - S Vazquez
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - M Pujol Lopez
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - R San Antonio
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - G Caldentey
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - J Ivey Miranda
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | | | - A Regueiro
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - X Freixa
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - I Ferreira
- University Hospital Vall d'Hebron, Barcelona, Spain
| | - M Sabate
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| |
Collapse
|
22
|
Jonasch E, Procopio G, Hawkins RE, Rodriguez Sanchez A, Vazquez S, Srihari N, Kalofonos H, Bamias A, Bono P, Babanrao Pisal C, Hirschberg Y, Dezzani L, Ahmad QI, Schmidinger M. Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.4561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Eric Jonasch
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Robert E. Hawkins
- The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
| | | | | | | | | | | | - Petri Bono
- Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Helsinki, Finland
| | | | | | - Luca Dezzani
- Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | | | | |
Collapse
|
23
|
Schmidinger M, Procopio G, Hawkins RE, Rodriguez Sanchez A, Vazquez S, Srihari N, Kalofonos H, Bamias A, Bono P, Babanrao Pisal C, Hirschberg Y, Dezzani L, Ahmad QI, Jonasch E. Prospective, multinational, observational study of real-world treatment outcomes with pazopanib in patients with advanced or metastatic renal cell carcinoma (PRINCIPAL study). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.4574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Robert E. Hawkins
- The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
| | | | | | | | | | | | - Petri Bono
- Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Helsinki, Finland
| | | | | | - Luca Dezzani
- Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | | | - Eric Jonasch
- The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
24
|
Lozano R, Romero-Laorden N, del Pozo A, Medina A, Mendez MJ, Morales Barrera R, Gonzalez del Alba AA, Rodriguez-Vida A, Hernandez A, Silla-Castro JC, Vazquez S, Gonzalez B, Pinto A, Perez Gracia JL, Querol R, Cañadilla V, Domenech M, Pritchard C, Castro E, Olmos D. Comparative assessment of abiraterone or enzalutamide activity in the PROREPAIR-B study. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.6_suppl.164] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
164 Background: Germline mutations in DNA repair genes have been associated with poor prostate cancer outcomes in retrospectives studies. Such defects have been identified in 12% of mCRPC patients. Several studies are ongoing to assess the benefit of these patients from platinum-based chemotherapy and PARP inhibitors, but no conclusive data are available with regards to currently approved therapies for mCRPC, as Abiraterone or Enzalutamide. Methods: PROREPAIR-B (NCT03075735) is a prospective multicentre observational cohort study. Patients diagnosed with mCRPC, with unknown mutational status at study entry and who were going to start a first-line treatment for mCRPC were eligible. For this sub-analysis patients who received Abiraterone or Enzalutamide as first androgen receptor targeted therapy (ART) were selected. The endpoints of this sub-analysis included to assess the impact of BRCA1, BRCA2, ATM, PALB2 and other germline mutations in DNA repair genes on cause-specific survival (CSS), progression-free survival (PFS), time to PSA progression (bPFS) and response to the first ART received as 1st or 2nd line therapy. Results: 337 patients were eligible for this analysis. CSS from mCRPC was not significantly different between gDDR carriers and non-carriers. However, CSS from mCRPC in BRCA2 carriers was significantly shorter than in non-carriers (23.3 Vs 34.6 months, p = 0.02). CSS from first ART, PFS and response-rates were not significantly different between both groups. However, the bPFS was significantly shorter in patients harbouring gDDR mutations (7.3 Vs 3.8 months, p = 0.04), especially in BRCA2 carriers (7.3 Vs 3.0 months, p = 0.03). Conclusions: This is the first study to prospectively follow-up DNA repair germline mutations to determine the outcome on standard treatment for mCRPC. The results suggest that different gDDR defects may have different impact on mCRPC outcomes. Clinical trial information: NCT03075735.
Collapse
Affiliation(s)
- Rebeca Lozano
- Spanish National Cancer Research Centre, Madrid, Spain
| | | | - Angela del Pozo
- Medical Genetics and Molecular Institute, La Paz, Madrid, Spain
| | - Ana Medina
- Centro Oncologico de Galicia, La Coruna, Spain
| | | | | | | | | | | | | | | | | | | | | | - Rosa Querol
- Hospital de Sabadell, Corporació Sanitària Parc Taulí, Institut Oncològic del Vallès, Sabadell, Spain
| | | | | | | | - Elena Castro
- Spanish National Cancer Research Centre, Madrid, Spain
| | - David Olmos
- Spanish National Cancer Research Centre, Madrid, Spain
| |
Collapse
|
25
|
Abele D, Vazquez S, Buma AGJ, Hernandez E, Quiroga C, Held C, Frickenhaus S, Harms L, Lopez JL, Helmke E, Mac Cormack WP. Pelagic and benthic communities of the Antarctic ecosystem of Potter Cove: Genomics and ecological implications. Mar Genomics 2017; 33:1-11. [PMID: 28479280 DOI: 10.1016/j.margen.2017.05.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2016] [Revised: 05/02/2017] [Accepted: 05/02/2017] [Indexed: 12/12/2022]
Abstract
Molecular technologies are more frequently applied in Antarctic ecosystem research and the growing amount of sequence-based information available in databases adds a new dimension to understanding the response of Antarctic organisms and communities to environmental change. We apply molecular techniques, including fingerprinting, and amplicon and metagenome sequencing, to understand biodiversity and phylogeography to resolve adaptive processes in an Antarctic coastal ecosystem from microbial to macrobenthic organisms and communities. Interpretation of the molecular data is not only achieved by their combination with classical methods (pigment analyses or microscopy), but furthermore by combining molecular with environmental data (e.g., sediment characteristics, biogeochemistry or oceanography) in space and over time. The studies form part of a long-term ecosystem investigation in Potter Cove on King-George Island, Antarctica, in which we follow the effects of rapid retreat of the local glacier on the cove ecosystem. We formulate and encourage new approaches to integrate molecular tools into Antarctic ecosystem research, environmental conservation actions, and polar ocean observatories.
Collapse
Affiliation(s)
- D Abele
- Dept. Biosciences, Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research, Am Handelshafen 12, 27470 Bremerhaven, Germany.
| | - S Vazquez
- Universidad de Buenos Aires, CONICET, Instituto de Nanobiotecnología (NANOBIOTEC), Junín 954, 1113 Buenos Aires, Argentina
| | - A G J Buma
- Dept. Ocean Ecosystems, Energy and Sustainability Research Groningen, University of Groningen, Nijenborgh 7, 9747 AG Groningen, The Netherlands
| | - E Hernandez
- Instituto Antártico Argentino (IAA), 25 de Mayo 1143, 1650 San Martin, Buenos Aires, Argentina
| | - C Quiroga
- Universidad de Buenos Aires, CONICET, Instituto de Medicina y Parasitologia Medica (IMPaM), Paraguay 2155 P.12, 1121 Buenos Aires, Argentina
| | - C Held
- Dept. Biosciences, Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research, Am Handelshafen 12, 27470 Bremerhaven, Germany
| | - S Frickenhaus
- Dept. Biosciences, Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research, Am Handelshafen 12, 27470 Bremerhaven, Germany
| | - L Harms
- Dept. Biosciences, Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research, Am Handelshafen 12, 27470 Bremerhaven, Germany
| | - J L Lopez
- Universidad de Buenos Aires, Catedra de Virologia, Junín 954, 1113 Buenos Aires, Argentina
| | - E Helmke
- Dept. Biosciences, Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research, Am Handelshafen 12, 27470 Bremerhaven, Germany
| | - W P Mac Cormack
- Instituto Antártico Argentino (IAA), 25 de Mayo 1143, 1650 San Martin, Buenos Aires, Argentina
| |
Collapse
|
26
|
Lozano A, Navarro A, Letelier H, Vazquez S, Navarro V, Nogues J, Mesia R. PO-058: Nasopharingeal carcinoma treated with intensity modulated radiotherapy in an non–endemic area. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30192-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
27
|
Ortega A, Domenech M, Falo C, Gil M, Stradella A, Fernandez A, Morilla I, Villanueva R, Castany R, Vazquez S, Molina K, Bergamino M, Navarro V, Pernas S. Abstract P4-21-32: Treatment of early HER2-positive breast cancer in trastuzumab era in everyday clinical practice: An overview after 10 years of its approval. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The addition of Trastuzumab(T) to chemotherapy (CT) revolutionized HER2-positive breast cancer(BC) and changed its natural history. We reviewed the efficacy of T outside clinical trials in a cancer comprehensive center.
Methods: Ambiespective and descriptive study was conducted in Catalan Institute of Oncology (ICO-Barcelona). Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with LogRank test. The association of clinic-pathological variables and outcome was studied by χ2and Cox proportional hazard analysis.
Results: 430 consecutive early HER2-positive BC patients (pts) were treated with adjuvant/neoadjuvant T and CT from Jan 2005 to Dec 2012. Pt basal characteristics are reported in Table 1. Neoadjuvant treatment was administrated in 230pts (54%) and in 200 (46%) in adjuvancy. Pathological complete response (pCR) in breast and nodes (ypT0/isypN0) was achieved in 48% of pts, with higher rates in hormone receptor (HR)-negative pts (62 vs 37% p=0.0005). Median duration of T: 10.6 months (m). 28%pts treated with neoadjuvant T+CT who achieved a pCR did not receive adjuvant T. Treatment discontinuation: 38pts (8.8%): 27pts due to cardiac toxicity and 4 relapsed during adjuvant T. In 87%pts, neoadjuvant CT was based on anthracyclines(A) and taxanes. Adjuvant CT: A and taxanes in 57.4%; 14%pts FAC, 15.4% A-CMF and 12% TCH. At a median follow-up of 70m (3-135), 44pts (10.4%) had relapsed: 33pts with distant M1, 9pts with only loco-regional disease and 2pts contralateral HER2-positive BC. M1 location: 46% visceral, 34% bone/lymph nodes and 20% in central nervous system (CNS). PFS was 23.4m(0-88); median OS was not reached; estimated 10 years-OS was 86.5%. Pts treated with A and taxanes had a significantly better OS compared to those treated with other CT (113 vs 98m, p= 0.009). Kaplan-Meier curve showed numerically higher relapses at 10 years in HR-positive pts (83 vs 90% p=0.8). Pts with pCR had significantly better OS (113 vs 104m, p=0.006). Pts with CNS-metastases had a significantly worse OS (13 vs 26m,p=0,02) and those with HR-negative (49 vs 24m, p= 0.033).
Conclusion: In everyday clinical practice, recurrences after adjuvant/neoadjuvant trastuzumab in HER2-positive BC were less than described in the T-pivotals trials, with 10% of recurrences at a median of FU of 70m. In our series, estimated 10 years-OS was 86.5%. Pts treated with A and taxanes had a significantly better OS as well as those pts who achieved a pCR. On the contrary, pts with CNS M1 and those with HR-negative had worse prognosis.
Table 1Median age51.9y (27-83)Stage I/II/III106 (25%)/ 226 (52%)/ 97 (23%)HR Positive/ Negative249 (58%)/181 (42%)
Citation Format: Ortega A, Domenech M, Falo C, Gil M, Stradella A, Fernandez A, Morilla I, Villanueva R, Castany R, Vazquez S, Molina K, Bergamino M, Navarro V, Pernas S. Treatment of early HER2-positive breast cancer in trastuzumab era in everyday clinical practice: An overview after 10 years of its approval [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-32.
Collapse
Affiliation(s)
- A Ortega
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - M Domenech
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - C Falo
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - M Gil
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - A Stradella
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - A Fernandez
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - I Morilla
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - R Villanueva
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - R Castany
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - S Vazquez
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - K Molina
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - M Bergamino
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - V Navarro
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - S Pernas
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| |
Collapse
|
28
|
Juan Ó, Vazquez S, Rubio JC, Fírvida JL, Aparisi F, Muñóz J, Sánchez JG, Gironés R, Quintela ML, Giner V, Hernández AS. P2.02-012 Long-Term Survival of Phase II of Full-Dose Oral Vinorelbine Combined with Cisplatin & Radiotherapy in Locally Advanced NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.1159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Oliva M, Taberna M, Iriarte AR, Bergamino M, Rovira A, Montal R, Hurtos L, Arribas L, Vilajosana E, Lozano A, Navarro V, Vazquez S, Maños M, Mesía R. Comorbidity and nutritional factors influence on bioradiotherapy (BRT) outcome in head and neck squamous cell carcinoma (HNSCC) patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw376.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Grande E, Fernández Pérez M, Font A, Vazquez S, Mellado B, Fernandez Calvo O, Méndez Vidal M, Climent M, González del Alba A, Gallardo E, Rodríguez Sánchez A, Santander C, Sáez M, Duran I, Puente J, Alonso Gordoa T, Tudela J, Martínez A, Castellano D, González Billalabeitia E. Early responses to enzalutamide in AR-V7 positive first line metastatic castration-resistant prostate cancer (mCRPC). A prospective SOGUG clinical trial: The PREMIERE study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw372.10] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Hurtós L, Oliva M, Bergamino M, Rullan A, Taberna M, Vazquez S, Mesia R, Vilajosana E, Lozano A, Arribas L. SUN-P091: Evolution of Nutritional Status in Locally Advanced Head and Neck (LAHNC) Patients Treated with Bioradiotherapy (BRT). Clin Nutr 2016. [DOI: 10.1016/s0261-5614(16)30434-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Vazquez S, Saez E, Martín M, Cava F. Evaluation of the new Siemens kPCR PLX® Herpes Simplex virus 1 and 2 (HSV) and kPCR PLX® Varicella-Zoster virus (VZV) DNA assays. Comparison analysis with the HSV1/2, VZV R-gene® qualitative assay from bioMérieux. J Clin Virol 2015. [DOI: 10.1016/j.jcv.2015.07.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Verdaguer Mata H, Laquente B, Busquets J, Pelaez N, Secanella L, Leiva D, Ruiz S, Peiro I, Lopez Urdiales R, Serrano T, Vazquez S, Calvo M, Serra O, Cambray M, Perez Martin F, Sanchez C, Galan M, Fabregat J. P-183 Neoadjuvant treatment in borderline resectable pancreatic adenocarcinoma (PA): A single center series. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Espino L, Barreiro JD, Gonzalez A, Santamarina G, Miño N, Vazquez S. Intracranial epidural empyema due toCryptococcus neoformansin a 5-year-old neutered male European short hair cat. Vet Q 2014; 35:51-5. [DOI: 10.1080/01652176.2014.993094] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
35
|
Duran I, Hagen C, Arija JA, Apellaniz M, Pérez-Valderrama B, Sala Gonzalez N, Lainez N, Garcia Del Muro X, Nogueron E, Climent M, Maroto P, Font A, Garcia-Donas J, Gallardo E, Lopez Criado P, Gonzalez Del Alba A, Saez M, Vazquez S, Luque R, Rodriguez-Antona C. Pharmacogenetic Study of Cabazitaxel in Advanced or Metastatic Transitional Cell Carcinoma (Tcc): the Sogug 2011-04 Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu337.62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Balana C, Sanz C, Ramirez J, Gil J, Sepúlveda J, De Las Penas R, Luque R, Gallego O, Reynes G, Carrato C, Sanchez B, Herrero A, Berrocal A, Perez Segura P, Garcia Castano A, Peralta S, Vazquez S, Fernández Perez I, Martinez-Garcia M. Mgmt Methylation in Tissue and Serum from Unresectable Glioblastoma (Gbm) Patients (P) Included in the Genom 009 Study, a Multicenter Randomized Study By the Geino Group Comparing Temozolomide (Tmz) Versus Tmz-Plus-Bevacizumab (Bev). (Clinicaltrials.Gov Nct01102595). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu330.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Hitt R, Mesia R, Grau J, Rubió J, Martínez-Trufero J, Del Barco Morillo E, Almodóvar Alvarez C, Taberna-Sanz M, García-Girón C, Vazquez S, Cirauqui B, Pastor Borgoñón M, Galve Calvo E, Juan-Vidal O, Lopez R, Martinez-Galan J, Bastus R, Berrocal A, Adansa Klain J, Cruz Hernandez J. Induction Chemotherapy (Ict) with Docetaxel/Cisplatin/5-Fluorouracil (T/P/F) Followed By Chemoradiotherapy with Cisplatin (Crtp) Vs Bioradiotherapy with Cetuximab (Rtcx) for Unresectable Locally Advanced Head & Neck Cancer (Ulahnc): Preliminary Results on Toxicity a Ttcc Group Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu340.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Sepúlveda J, Vieitez J, Vazquez S, Rodriguez Sanchez A, Gallego O, Rodríguez L, Andrade J, González F, Pujol E, Gil Gil M. Patient Profile and Therapeutic Management in Glioblastoma (Gbm): a Subgroup Analysis of a Large Prospective Observational Study of the Neuro-Oncology Investigation Spanish Group (Geino). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu330.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Caeiro M, Gomez A, Casal J, Leiva R, Lazaro M, Vazquez S, Pena C, Grande C, Carballo A. Prophylactic cranial irradiation (PCI) in non small cell lung cancer (NSCLC). Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
40
|
Firvida J, Vazquez S, Casal J, Alonso M, Varela S, Villanueva M, Afonso F, Fernandez O, Areses C, Campos B. Erlotinib as Frontline Treatment for Elderly Patients (P) with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC): Ggcp044/09 Study. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33794-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
41
|
Rubio JC, Taboada B, Lazaro M, Vazquez S, Firvida X, Villar MV, Hernández E, Castro J, Barón F, Pena C. Concurrent Chemoradiation (CCHRT) with Bi-Weekly Docetaxel and Cisplatin and Thoracic Radiotherapy for Stage III Non-Small Cell Lung Cancer (NSCLC): A Phase II Study from the Galician Lung Cancer Group. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33766-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
42
|
Lázaro M, Varela S, Vazquez S, Villanueva M, Firvida J, Amenedo M, Afonso F, Senin C, Grande C. 9099 POSTER Biweekly Docetaxel-Cisplatin in Chemonaive Patients With Advanced Epidermoid Carcinoma of the Lung – a Phase II Study of Galician Lung Cancer Group. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72411-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
43
|
Martinez-Poveda B, Gomez V, Alcaide-German M, Perruca S, Vazquez S, Alba LE, Casanovas O, Garcia-Bermejo ML, Peso L, Jimenez B. Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma. Int J Oncol 2011; 39:543-52. [PMID: 21667025 DOI: 10.3892/ijo.2011.1074] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2011] [Accepted: 05/16/2011] [Indexed: 11/05/2022] Open
Abstract
Targeting the hypoxia response pathway and angiogenesis are two promising therapeutic strategies for cancer treatment. Their use as single strategies has important limitations. Thus, development of combined regimens has become an important step toward improving therapeutic efficacy. Also, non-invasive monitoring of the response to targeted biological therapies, as well as determination of the optimal schedule for combination regimens has become an active field of research over the last five years, with relevance for both preclinical and clinical settings. Here, we used an optical imaging method to non-invasively monitor the functional changes in HIF activity in response to antiangiogenic treatment in a xenograft model of human ovarian carcinoma. A bioluminescent reporter construct containing nine copies of the hypoxia response element upstream of the luciferase gene (9xHRE-luciferase) was characterized in vitro in a panel of tumor cell lines and in vivo in a subcutaneous xenograft model of ovarian carcinoma by means of optical imaging. We showed that in OVCAR-3 subcutaneous xenografts, the most abrupt change in the HIF functional reporter occurs before the onset of massive tumor growth. However, this system failed to detect hypoxia induced upon antiangiogenic treatment due to the compensating effects of increased hypoxia and decreased tumor cell viability caused by imbalanced neovascularization vs. tumor expansion. Therefore, the readout based on HIF functional reporter could be conditioned by the dynamics of tumor growth and angiogenesis, which is highly variable depending on the tumor type, tumor model and stage of progression.
Collapse
Affiliation(s)
- B Martinez-Poveda
- Departamento de Bioquímica, Instituto de Investigaciones Biomédicas (CSIC-UAM), 28029 Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Song S, Stevanov K, Vazquez S, Tran H. Discovering the do's and don'ts of drugs of abuse analysis — Opiates. Clin Chim Acta 2010. [DOI: 10.1016/j.cca.2010.02.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
45
|
Vazquez S, Firvida J, Lázaro M, Barón FJ, Alonso-Jaudenes Curbera G, Amenedo M, Santomé L, Afonso FJ, Cardona JV, Casal J. A Galician Lung Cancer Group phase II study: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7091] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Leon L, Vazquez S, Gracia J, Casal J, Lázaro M, Fírvida JL, Amenedo M, Santomé L, Cardona JV, Maciá S. A Galician Lung Cancer Group phase II study of bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Vazquez S, Leon L, Gracia J, Casal J, Lazaro M, Firvida J, Amenedo M, Santome L, Cardona J, Macia S. 9145 Bevacizumab (B), cisplatin and vinorelbine in chemo-naïve patients (P) with non squamous non small cell lung cancer (NSCLC): a galician lung cancer group phase II study. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71858-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
48
|
Andrés A, Polanco N, Cebrian M, Sol Vereda M, Vazquez S, Nuño E, Bello T, Gutierrez E, Gonzalez E, Praga M, Morales E, Morales J, Leiva O, Aguirre F, Diaz R. Kidneys From Elderly Deceased Donors Discarded for Transplantation. Transplant Proc 2009; 41:2379-81. [DOI: 10.1016/j.transproceed.2009.06.156] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Luthy I, Bruzzone A, Pinero C, Castillo L, Chiesa I, Vazquez S, Sarappa M. Adrenoceptors: Non Conventional Target for Breast Cancer? Curr Med Chem 2009; 16:1850-62. [DOI: 10.2174/092986709788186048] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
50
|
Pueyo G, Mesia R, Lozano A, Vazquez S, Capella G, Balart J. Inhibitory Effect of Cetuximab on Radiation-resistant A431 Cells: An In Vivo Model. Int J Radiat Oncol Biol Phys 2008. [DOI: 10.1016/j.ijrobp.2008.06.1227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|